The clinical management of the AUS/FLUS diagnostic group has represented an ongoing challenge. Even though many cases with an AUS/FLUS BSRTC diagnosis undergo a repeat FNAB, there has also been much research that has focused on the application of adjunctive molecular testing for facilitating appropriate clinical management. Such strategies add significant complexity and cost to patient management. However, age is an easily accessible patient characteristic that has received little attention in the literature with regards to its influence on patient ROM within the BSRTC diagnostic categories. In the current study, all patients were stratified into two groups, those younger than 55 years, and those 55 years or older, a cut-off point we selected because it also represents an important thyroid cancer clinical prognosticator that has been recently incorporated into the eighth edition of the American Joint Committee on Cancer (AJCC) Differentiated Thyroid Cancer Staging System . We observed a statistically significant difference in the ROM in patients with an AUS/FLUS diagnosis who were younger than 55 years, with the ROM being 36.8% in the younger group, compared to 7.4% in the older group. This suggests that thyroid nodules with an AUS/FLUS diagnosis, although being more common and generally having a worse prognosis when diagnosed as malignancy in older people, tend to have a higher risk of actually being diagnosed as cancer when detected in younger people. Other groups have also made similar observations . Thus, when utilizing the BSRTC, patient age should be taken into account in order to facilitate a more accurate estimate of their actual ROM. Recently, when used in conjunction with other clinical parameters such as nodule size, and ultrasound characteristics, patient age has been found to be a predictive factor for malignancy in patients younger than 65 years .